NCT05020652View on ClinicalTrials.gov

A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis

PHASE2UnknownINTERVENTIONAL
Enrollment

105

Participants

Timeline

Start Date

November 11, 2021

Primary Completion Date

March 31, 2023

Study Completion Date

September 30, 2023

Conditions
Moderate and High Risk Myelofibrosis
Interventions
DRUG

TQ05105 tablets

TQ05105 tablet is a JAK2 inhibitor, which can be used to treat JAK2 target related diseases, such as moderate or high-risk multiple myelofibrosis.

DRUG

Hydroxycarbamide tablets

Hydroxycarbamide tablet is a nucleoside diphosphate reductase inhibitor.

Trial Locations (4)

100005

RECRUITING

Peking Union Medical College Hospital, Beijing

300020

RECRUITING

Institute of Hematology & Blood Diseases Hostpital, Chinese Academy of medical sciences & Peking Union Medical College, Tianjin

510055

RECRUITING

Guangdong Provincial Peoples Hospital, Guangzhou

610041

RECRUITING

West China School of Medicine / West China Hospital, Sichuan University, Chengdu

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY